A qualitative and quantitative risk assessment of snuff dipping

Regulatory Toxicology and Pharmacology

Volumn 28, Issue 1, 1998, Pages 1-16

  Nilsson, Robert ^a  

^a STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROQUINOLINE 1 OXIDE; 7,12 DIMETHYLBENZ[A]ANTHRACENE; ALKALOID DERIVATIVE; ANABASINE; ANATABINE; ARECOLINE; BIS(2 HYDROXYETHYL)NITROSAMINE; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; DIMETHYLNITROSAMINE; ISOTHIOCYANIC ACID; MORPHOLINE; MYOSMINE; N NITROSOPYRROLIDINE; NITRATE; NITROSAMINE; NITROSOMORPHOLINE; NITROSONORNICOTINE; PHENETHYL ISOTHIOCYANATE; PHENETYLISOTHIOCYANATE; PLANT EXTRACT; TOBACCO SMOKE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CANCER RISK; CARCINOGENICITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DNA ADDUCT; DOSE RESPONSE; FEMALE; GENOTOXICITY; GOOD MANUFACTURING PRACTICE; HUMAN; MALE; MOUTH CANCER; NITROSATION; NONHUMAN; PACKAGING; PHARYNX CANCER; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; SMOKELESS TOBACCO; SMOKING; SWEDEN; TOBACCO INDUSTRY; TOXICITY TESTING; UNITED STATES;

EID: 0031755281     PISSN: 02732300     EISSN: None     Source Type: Journal    
DOI: 10.1006/rtph.1998.1229     Document Type: Article

References (113)

1. Ahlbom, A. Olsson, U. A. Pershagen, G. 1996, Health Risks Associated with Snuff.
2. Andersson G., Axéll T. The clinical appearance of lesions associated with the use of loose and portion-bag packed Swedish moist snuff: A comparative study. J. Oral Pathol. Med. 18:1989;2-7.
3. Andersson G., Björnberg G., Curvall M. Oral mucosal changes and nicotine disposition in users of Swedish smokeless tobacco products: A comparative study. J. Oral Pathol. Med. 23:1994;161-167.
4. Axéll T. Oral mucosal changes related to smokeless tobacco usage: Research findings in Scandinavia. Oral Oncol. Eur. J. Cancer. 29B:1993;299-302.
5. Axéll T., Mörnstad H., Sundström B. The relation of the clinical picture to the histopathology of snuff dipper's lesion in a Swedish population. J. Oral Pathol. 5:1976;229-236.
6. Belinsky S. A., White C. M., Boucheron J. A., Richardson F. C., Swenberg J. A., Anderson M. W. Accumulation and persistence of DNA adducts in respiratory tissue of rats following multiple administrations of the tobacco specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res. 46:1986;1280-1284.
7. Belinsky S. A., Devereux T. R., Maronpot R. R., Stoner G. D., Anderson M. W. Relationship between the formation of promutagenic adducts and the activation of the K-ras. Cancer Res. 49:1989;5305-5311.
8. 6. Cancer Res. 50:1990;3772-3780.
9. Benoni C., Nilsson Å. Smoking habits in patients with inflammatory bowel disease. A case control study. Scand. J. Gastroenterol. 22:1987;1130-1136.
10. Blömeke B., Greenblatt M. J., Doan V. D., Bowman E. D., Murphy S. E., Chen C. C., Kato S., Shields P. G. Distribution of 7-alkyl-2′-deoxuguanosine adduct levels in human lung. Carcinogenesis. 17:1996;741-748.
11. Bolinder, G. 1997, Long term use of smokeless tobacco: Cardiovascular mortality and risk factors, Karolinska Institute, Stockholm, November 1997.
12. Bolinder G., Himmelmann L. Less smokers but more snuff dippers: 28-years of follow-up of the tobacco habits of Swedish physicians. Läkartidningen (J. Swed. Med. Assoc.). 93:1996;4437-4444.
13. Bolinder G., Ahlborg B. O., Lindell J. H. Use of smokeless tobacco: Blood pressure elevation and other health hazards found in a large-scale population survey. J. Internal Med. 232:1992;327-334.
14. Bolinder G., Alfredsson L., Englund A., de Faire U. Smokeless tobacco use and increased cardiovascular mortality among Swedish construction workers. Am. J. Publ. Health. 84:1994;399-404.
15. Bolinder G., Norén A., de Faire U., Wahren J. Smokeless tobacco use and atherosclerosis: An ultrasonographic investigation of carotid intima media thickness in healthy middle-aged men. Atherosclerosis. 132:1997;95-103.
16. Brunnemann K. D., Hoffmann D. Analytical studies onN. Rec. Adv. Tobacco Sci. 17:1991;71-112.
17. Brunnemann K. D., Scott. J. C., Hoffmann D. NN. Carcinogenesis. 3:1982;693-696.
18. Brunnemann K. D., Rivenson A., Adams J. D., Hecht S. S., Hoffmann D. A study of snuff carcinogenesis. IARC Sci. Publ. 84:1987;456-459.
19. Carmella S. G., Hecht S. S. Formation of hemoglobin adducts upon treatment of F344 rats with the tobacco specific nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone andN. Cancer Res. 47:1987;2626-2630.
20. Carmella S. G., Kagan S. S., Kagan M., Foiles P. G., Palladino G., Quart A. M., Quart E., Hecht S. S. Mass spectrometric analysis of tobacco-specific nitrosamine hemoglobin adducts in snuff dippers, smokers, and nonsmokers. Cancer Res. 50:1990;5438-5445.
21. Carmella S. G., Kagan S. S., Hecht S. S. Evidence that a hemoglobin adduct used for dosimetry of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a carboxylic ester. Environ. Health Perspect. 99:1993a;203-205.
22. Carmella S. G., Akerkar S., Hecht S. S. Metabolites of the tobacco-specific nitroamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers' urine. Cancer Res. 53:1993b;721-724.
23. Castonguay A., Rivenson A., Trushin N., Reinhardt J., Spathopolous S., Weiss C. J., Reiss B., Hecht S. S. Effects of chronic ethanol consumption on the metabolism and carcinogenicity ofN. Cancer Res. 44:1984;2285-2290.
24. Cholerton S., Arpanhal A., McCracken N., Boustead C., Taber H., Johnstone E., Leathart J., Daly A. K., Idle J. R. Poor metabolisers of nicotine and CYP2D6 polymorphism. Lancet. January 1:1994;62-63.
25. Chung F.-L., Juchatz A., Vitarius J., Hecht S. S. Effects of dietary compounds on α-hydroxylation ofNN. Cancer Res. 44:1984;2924-2928.
26. CPS, 1997, Current Population Survey, 1992-1993. State & National Tobacco Control Highlights, http://www.cdc.gov/nccdphp/osh/sltmen.htm.
27. Crump K. An improved procedure for low-dose carcinogenic risk assessment from animal data. J. Environ. Pathol. Toxicol. 5:1982;339-348.
28. Djordjevic M. V., Fan J., Bush L. P., Brunnemann D., Hoffmann D. Effects of storage conditions on levels of tobacco-specificNN. J. Agr. Food Chem. 41:1993;1790-1794.
29. Doll R., Peto R. The causes of cancer: Quantitative estimates of avoidable risks of cancer in the United States today. J. Natl. Cancer Inst. 66:1981.
30. Ehrenberg L., Hiesche K. D., Osterman-Golkar S., Wennberg I. Evaluation of genetic risks of alkylating agents: Tissue doses in the mouse from air contaminated with ethylene oxide. Mutat. Res. 24:1974;83-103.
31. Ehrenberg L., Moustacchi E., Osterman-Golkar S. Dosimetry of genotoxic agents and dose-response relationships of their effects, with an Appendix II by G. Ekman, Working paper of the International Commission for Protection against Environmental Mutagens and Carcinogens (ICPEMC), Committee 4. Mutat. Res. 123:1983;121-182.
32. Ehrenberg L., von Bahr B., Ekman G. Register analysis of measures of urbanization and cancer incidence in Sweden. Environ. Int. 11:1985;393-399.
33. Eliasson M., Asplund K., Evrin P. E., Lundblad D. Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic variables and serum insulin. The Northern Sweden MONICA study. Atherosclerosis. 113:1995;41-53.
34. Frithiof L., Anneroth G., Larsson U., Sederholm C. The snuff induced lesion: A clinical and morphological study of a Swedish material. Acta Odontol. Scand. 41:1983;53-64.
35. Griciute L., Castegnaro M., Bereziat J. C., Cabral J. R. P. Influence of ethyl alcohol on the carcinogenic activity ofN. Cancer Lett. 31:1986;267-275.
36. Guo Z., Smith T. J., Thomas P. E., Yang C. S. Metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone as measured by DNA alkylationin vitro: Cancer Res. 51:1991;4798-4803.
37. Hansson L.-E., Baron J., Nyrén O., Bergström R., Wolk A., Adami H.-O. Tobacco, alcohol and the risk of gastric cancer. A population based case-control study in Sweden. Int. J. Cancer. 57:1994;26-31.
38. Hecht S. S. Recent studies on the mechanism of bioactivation and detoxification of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific lung carcinogen. Crit. Rev. Toxicol. 26:1996;163-181.
39. Hecht S. S., Lin D., Chen C. B. Comprehensive analysis of urinary metabolites ofN. Carcinogenesis. 2:1981;833-838.
40. Hecht S. S., Young R., Masura Y. Comparative carcinogenicity in F3444 rats and Syrian golden hamsters ofNNN. Cancer Lett. 20:1983;333-340.
41. Hecht S. S., Rivenson A., Braley J., DiBello J., Adamas J. D., Hoffmann D. Induction of oral cavity tumors in F344 rats by tobacco-specific nitrosamines and snuff. Cancer Res. 46:1986;4162-4166.
42. Hecht S. S., Kagan S. S., Kagan M., Carmella S. G. Quantification of 4-hydroxy-1-(3-pyridyl)-1-butanone released from human hemoglobin as a dosimeter for exposure to tobacco-specific nitrosamines. Relevance to Human Cancer of N-Nitroso Compounds, Tobacco Smoke and Mycotoxins. 1991;IARC, Lyon. p. 113-118.
43. Hecht S. S., Carmella S. G., Foiles P. G., Murphy S. E., Peterson L. A. Tobacco specific nitrosamine adducts: Studies in laboratory animals and humans. Environ. Health Perspect. 99:1993;57-63.
44. Hecht S. S., Peterson L. A., Spratt T. E. Tobacco-specific nitrosamines. Hemminki. DNA Adducts: Identification and Biological Significance. 1994;91-106 IARC, Lyon.
45. Higginson J., Oettlé A. G. Cancer incidence in the Bantu and "Cape Colored" races in South Africa: Report of a cancer survey in the Transvaal (1953-1955). J. Natl. Cancer Inst. 24:1960;589-671.
46. Hirsch J. M., Heyden G., Thilander H. A clinical, histomorphological and histochemical study on snuff-induced lesions of varying severity. J. Oral Pathol. 11:1982;387-398.
47. Hoffmann D., Adams J. D., Brunnemann K. D., Hecht S. S. Formation, occurrence, and carcinogenicity ofN. ACS Am. Chem. Soc. 174:1981;247-273.
48. Hoffmann D., Rivenson A., Amin S., Hecht S. S. Dose-response study of the carcinogenicity of tobacco-specificN. J. Cancer Res. Clin. Oncol. 108:1984;81-86.
49. Hoffmann D., Djordjevic M. V., Brunnemann K. D. New brands of oral snuff. Food Chem. Toxicol. 29:1991;65-68.
50. Hoffmann D., Djordjevic M. V., Fan J., Zang E., Glynn T., Connolly G. N. Five leading U.S. commercial brands of moist snuff in 1994: Assessment of carcinogenicN. J. Natl. Cancer Inst. 87:1995;1862-1869.
51. Hoffmann D., Melikian A. A., Wynder E. L. Scientific challenges in environmental carcinogenesis. Prev. Med. 25:1996;14-22.
52. Hoffmann and Djordjevic M. V. Chemical composition and carcinogenicity of smokeless tobacco. Adv. Dent. Res. 11:1997;322-329.
53. Huhtasaari F., Asplund, Wester P. O. Cardiovascular risk factors in the Northern Sweden MONICA study. Acta Med. Scand. 224:1988;99-108.
54. Huhtasaari F., Asplund K., Lundberg V., Stegmayr B., Wester P. O. Tobacco and myocardial infarction: Is snuff less dangerous than cigarettes. Br. Med. J. 305:1992;1252-1256.
55. IARC Monographs on the Evaluation of the Carcinogenic Risks to Humans - Tobacco Habits Other Than Smoking: Betel-Qid and Areca Nut Chewing and Some Related Nitrosamines. 1985;WHO, Lyon.
56. Cancer Incidence in Five Continents. 1992;WHO, Lyon.
57. Idris A. M., Nair J., Oshima H., Friesen M., Brouet I., Faustman E. M., Bartsch H. Unusually high levels of carcinogenic nitrosamines in Sudan snuff (Toombak). Carcinogenesis. 12:1991;1115-1118.
58. Idris A. M., Prokopczyk B., Hoffmann D. Toombak: A major risk factor for cancer of the oral cavity in Sudan. Prev. Med. 23:1994;832-839.
59. IRIS, 1995.
60. Jayant K., Balakrishnan V., Sanghvi L. D., Jussawalla D. J. Quantification of the role of smoking and tobacco chewing in oral, pharyngeal, and esophageal cancers. Br. J. Cancer. 35:1977;232.
61. Jenssen, D. Curvall, M. 1996, Mutagens and antimutagens in moist snuff, Health Risks Associates with Snuff.
62. Johansson S. L., Hirsch J. M., Larsson P. A., Said J., Österdahl B. G. Snuff-induced carcinogenesis: Effect of snuff in rats initiated with 4-nitroquinoline-N. Cancer Res. 49:1989;3063-3069.
63. Jungnell P., Malmström M. Snuff-induced lesions in Finnish recruits. Scand. J. Dent. Res. 93:1985;442-447.
64. Kresty L. A., Carmella S. G., Borukhova A., Akerkar S. A., Gopalakrishnan R., Harris R. E., Stoner G. D., Hecht S. S. Metabolites of a tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), in the urine of smokeless tobacco users: Relationship between urinary biomarkers and oral leukoplakia. Cancer Epidemiol. Biomarkers Prev. 5:1996;521-525.
65. Kirkland L. R. The nonsmoking uses of tobacco. New Engl. J. Med. 303:1980;165.
66. Larsson B. K., Sahlberg G. P., Eriksson A. T., Busk L. Å. Polycyclic aromatic hydrocarbons in grilled food. J. Agric. Food Chem. 31:1983;867-873.
67. Larsson Å., Axell T., Andersson G. Reversibility of snuff dippers' lesion in Swedish moist snuff users - A clinical and histologic follow-up study. J. Oral Pathol. Med. 21:1991.
68. Lee P. N., Forey B. A. Misclassification of smoking habits as a source of bias in the study of environmental tobacco smoke and lung cancer. Stat. Med. 15:1996;581-605.
69. Lewin F., Rutqvist L. E., Johansson H., Norell S., Wennerberg J. Risk factors for larynx: Case-control study of the head and neck. Proceedings of the 2nd World Conference on Laryngeal Cancer. 1994;Univ. Sydney, Sydney.
70. Lewin F., Norell S. E., Johansson H., Gustavsson P., Wennerberg J., Björklund A., Rutqvist L. E. Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck. A population based case-referent study in Sweden. Cancer. 82:1998;1367-1375.
71. Lindberg E., Tysk C., Anderssson K., Järnerot G. Smoking and inflammatory bowel disease. A case control study. Gut. 29:1988;352-357.
72. Morse M. A., Wang C.-X., Stoner G. D., Mandal S., Conran P. B., Amin S. G., Hecht S. S., Chung F.-L. Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced DNA adduct formation and tumorigenicity in the lung of F344 rats by dietary phenethyl isothiocyanate. Cancer Res. 49:1989;549-553.
73. Mullenders L. H. F., Vrieling H., Venema J., van Zeeland A. A. Hierarchies of DNA repair in mammalian cells: Biological consequences. Mutat. Res. 250:1991;223-228.
74. Murphy S. E., Palomino A., Hecht S. S., Hoffmann D. Dose-response study of DNA and hemoglobin adduct formation by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in F334 rats. Cancer Res. 50:1990;5446-5452.
75. Nyrén, O. 1998, Snuff dipping and oral cancer: A prospective study of a Swedish cohort.
76. Osborne M. J., Stansby G. P. Cigarette smoking and its relationship to inflammatory bowel disease: A review. J. Royal Soc. Med. 85:1992;214-216.
77. Örtendahl, C. 1997, Hazard Labeling of Packages of Snuff, February 6, 1997.
78. Örtendahl B.-G. Tobacco specific nitrosamines in snuff and chewing tobacco, 1983-1992. Analyses conducted by the National Swedish Food Agency. Health Risks Associates with Snuff. 1996.
79. Örtendahl B.-G., Slorach S. A. VolatileN. Food Chem. Toxicol. 21:1983;759-762.
80. Örtendahl B.-G., Slorach S. A. N. Food Addit. Contam. 1:1984;299-305.
81. Park N. H., Sapp J. P., Herbosa E. G. Oral cancer induced in hamsters with herpes simplex infection and simulated snuff dipping. Oral Surg. Oral Med. Oral Pathol. 62:1986;164-168.
82. 6. Cancer Res. 51:1991;5557-5564.
83. Pfaffenberger R. S., Hyde R. T., Wing A. L., Hsieh C. Zaridze D. G., Peto R. Tobacco: A Major International Health Hazard. 1986;IARC, Lyon.
84. Pindeborg J. J., Axelsen N. H. New age for non-smoked tobacco. Lancet. 1:1980;775.
85. Rivenson A., Hoffmann D., Prokopczyk B., Amin S., Hecht S. S. Induction of lung and exocrine pancreas tumors in F344 rats by tobacco specific and areca-derived N-nitrosamines. Cancer Res. 48:1988;6912-6917.
86. Rodu B. Editorial: An alternative approach to smoking control. Am. J. Med. Sci. 308:1994;32-34.
87. Roed-Petersen, B. Pindborg, J. J. A study of Danish snuff-induced oral leukoplakias, J. Oral Pathol. 2, 301, 313.
88. Rogozinski J. Smokeless Tobacco in the Western World: 1550-1950. 1990;Praeger, New York. p. 42-44.
89. Ronai Z. A., Gradia S., Peterson L. A., Hecht S. S. G to A transitions and G to T transversions in codon 12 of the Ki-ras. Carcinogenesis. 14:1993;2419-2422.
90. Russel M. A. H., Jarvis M. J., Feyerabend C. A new age for snuff. Lancet. 1:1980;474-475.
91. Samuelsson C. Medical consequences of polonium in snuff. Läkartidningen (J. Swed. Med. Assoc.). 86:1989;2290-2291.
92. Schildt E.-B., Erikssson M., Hardell L., Magnusson A. Oral snuff, smoking habits, and alcohol consumption in relation to oral cancer in a Swedish case-control study. Int. J. Cancer. 77:1998;341-346.
93. Schievelbein H. Schnupftabak. Deut. Med. Wochenschr. Praxis Forum. 105:1980;183.
94. Sciubba J. J. Oral leukoplakia. Crit. Rev. Oral Biol. Med. 6:1995;147-160.
95. Segerbäck D., Osterman-Golkar S., Molholt B., Nilsson R. In vivo. Reg. Toxicol. Pharmacol. 20:1994;1-14.
96. Sheen S. J. Detection of nicotine in foods and plant materials. J. Food Sci. 53:1988;1572-1573.
97. Smith J. F. Snuff dipper's lesions: A ten-year follow-up. Arch. Otolaryngol. 101:1975;2765-2770.
98. Stegmayr B., Johansson I., Huhtasaari F., Moser U., Asplund K. Use of smokeless tobacco and cigarettes - Effects on plasma levels of antioxidant vitamins. Int. J. Vitam. Nutr. Res. 63:1993;195-200.
99. Swedish Cancer Committee, 1984a, Cancer - Causes and Prevention. Report to the Ministry of Social Affairs from the Cancer Committee, 238.
100. Swedish Cancer Committee, 1984b, Cancer - Causes and Prevention. Report to the Ministry of Social Affairs from the Cancer Committee, L. Ehrenberg, Estimation of Cancer Risk due to Passive Smoking.
101. Tysk G., Järnerot G. Has smoking changed the epidemiology of ulcerative colitis. Scand. J. Gastroenterol. 27:1992;508-512.
102. Törnqvist M., Ehrenberg L. Approaches to risk assessment of automotive engine exhausts. Vainio H., Sorsa M., McMichael A. J. Complex Mixtures and Cancer Risk. 1990;277-287.
103. Törnqvist M., Mowrer J., Jensen S., Ehrenberg L. Monitoring of environmental cancer initiators through hemoglobin adducts by a modified Edman degradation method. Anal. Biochem. 154:1986;255-266.
104. United Nations (UN), 1998, Social and Economical Aspects of Reduction of Tobacco Smoking by Use of Alternative Nicotine Delivery Systems (ANDS), 22, 24, United Nations, Geneva.
105. U.S. EPA, 1996, Proposed Guidelines for Carcinogen Risk Assessment, Office of Research and Development, U.S. EPA, Washington, DC, 61, 17959, 18010.
106. Vigneswaran N., Dent M., Tilashalski K., Rodu B., Cole P. Tobacco use and cancer: A reappraisal. Oral Surg. Med. Pathol. 80:1995;178-182.
107. Waldron C. A., Schaffer G. Leukoplakia revisited: A clinico-pathologic study of 3256 oral leukoplakias. Cancer. 36:1975;1386-1392.
108. Wattenberg L. W. Inhibition of carcinogenic effects of polycyclic hydrocarbons by benzyl isothiocyanate and related compounds. J. Natl. Cancer Inst. 58:1977;395-398.
109. Wennmalm Å., Benthin G., Granström E. F., Persson L., Petersson A.-S., Winell S. Relation between tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in young men. Circulation. 83:1991;1698-1704.
110. Winn D. M. Smokeless tobacco and oral/pharynx cancer: The role of cofactors. Banbury Rep. 23:1986;361-375.
111. Winn D. M., Blot W. J., Shy C. M., Pickle L. W., Toledo A., Fraumeni J. F. Snuff dipping and oral cancer among women in the southern United States. New Engl. J. Med. 304:1981;745-749.
112. Wray A., McGuirt F. Smokeless tobacco usage associated with oral carcinoma. Arch. Otolaryngol. Head Neck Surg. 119:1993;929-933.
113. Wright A. S., Bradshaw T. K., Watson W. P. Prospective detection and assessment of genotoxic hazards: A critical appreciation of the contribution of L. Ehrenberg. Bartsch H., Hemminki K., O'Neill I. K. Methods for Detecting DNA Damaging Agents in Humans: Applications in Cancer Epidemiology and Prevention. 1988;237-248.